Trending NewsTrending NewsNASDAQ:QURE uniQure (QURE) Stock Price, News & Analysis $19.35 -0.88 (-4.35%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$20.51 +1.16 (+6.00%) As of 11/20/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About uniQure Stock (NASDAQ:QURE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get uniQure alerts:Sign Up Key Stats Today's Range$19.00▼$21.6050-Day Range$19.35▼$45.2852-Week Range$8.73▼$51.72Volume2.10 million shsAverage Volume1.93 million shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$55.58Consensus RatingModerate Buy Company Overview uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership. The company’s pipeline also includes therapies being evaluated in clinical studies. Founded in the Netherlands in 1998, uniQure traces its origins to Amsterdam Molecular Therapeutics. Its Glybera therapy became the first gene therapy to receive marketing authorization in the European Union, though it was later withdrawn from the market.AI Generated. May Contain Errors. Read More uniQure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreQURE MarketRank™: 2.83127456485 of 5 starsuniQure scored higher than 57% of companies evaluated by MarketBeat, and ranked 386th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatinguniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 11 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialuniQure has a consensus price target of $55.58, representing about 187.3% upside from its current price of $19.35.Amount of Analyst CoverageuniQure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about uniQure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($3.79) to ($3.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiouniQure has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.72% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 6.39.Change versus previous monthShort interest in uniQure has recently decreased by 2.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.44 News SentimentuniQure has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for uniQure this week, compared to 9 articles on an average week.Search InterestOnly 9 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have not sold or bought any company stock.Percentage Held by Insiders4.65% of the stock of uniQure is held by insiders.Percentage Held by Institutions78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about uniQure's insider trading history. Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QURE Stock News HeadlinesuniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $56.83November 20 at 3:58 AM | americanbankingnews.comuniQure (NASDAQ:QURE) Stock Price Target Cut by HC WainwrightNovember 20 at 2:18 AM | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.November 22 at 1:00 AM | Profits Run (Ad)uniQure: A Breakthrough In Huntington's, With A Market Too Large To IgnoreNovember 14, 2026 | seekingalpha.comIs uniQure (QURE) Priced Beyond Its Book Value Support?November 12, 2026 | finance.yahoo.comReduced Loss And Higher Revenue Could Shift The Case For uniQure StockNovember 5, 2026 | finance.yahoo.comUniQure outlines AMT-130 confirmatory study of ~200 patients with May 1, 2027 PDUFA date in focusNovember 4, 2026 | seekingalpha.comuniQure (QURE) Q3 2026 Earnings Call TranscriptNovember 4, 2026 | finance.yahoo.comSee More Headlines QURE Stock Analysis - Frequently Asked Questions How have QURE shares performed this year? uniQure's stock was trading at $23.93 at the beginning of the year. Since then, QURE shares have decreased by 19.1% and is now trading at $19.35. How were uniQure's earnings last quarter? uniQure N.V. (NASDAQ:QURE) released its quarterly earnings results on Wednesday, November, 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. The biotechnology company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.18 million. uniQure had a negative trailing twelve-month return on equity of 96.34% and a negative net margin of 1,154.84%. Read the conference call transcript. When did uniQure IPO? uniQure (QURE) raised $76 million in an initial public offering on Wednesday, February 5th 2014. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Who are uniQure's major shareholders? Top institutional investors of uniQure include State Street Corp (3.68%), Two Seas Capital LP (1.91%), Goldman Sachs Group Inc. (1.45%) and Assenagon Asset Management S.A. (1.00%). Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Walid Abi-Saab, Jeannette Potts, Kylie O'keefe, Pierre Caloz, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Leonard E Post, Rachelle Suzanne Jacques, Robert Gut and Jack Kaye. View institutional ownership trends. How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Salesforce (CRM), Tesla (TSLA) and Intel (INTC). Company Calendar Last Earnings11/04/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 QURE's financial health is in the Yellow zone, according to TradeSmith. QURE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QURE CIK1590560 Webwww.uniqure.com Phone(339) 970-7000Fax31-20-566-9272Employees221Year Founded1868Price Target and Rating Average Price Target for uniQure$55.58 High Price Target$75.00 Low Price Target$28.00 Potential Upside/Downside+187.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.97 million Net Margins-1,154.84% Pretax Margin-1,159.36% Return on Equity-96.34% Return on Assets-26.40% Debt Debt-to-Equity Ratio0.17 Current Ratio11.52 Quick Ratio11.52 Sales & Book Value Annual Sales$16.10 million Price / Sales84.30 Cash FlowN/A Price / Cash FlowN/A Book Value$4.20 per share Price / Book4.61Miscellaneous Outstanding Shares70,140,000Free Float66,878,000Market Cap$1.36 billion OptionableOptionable Beta1.14 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:QURE) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.